Ginkgo Bioworks Hldgs Inc (DNA)

$6.71 -0.20 (-2.89%)
Market Cap 393.23M
Revenue (ttm) 170.16M
Net Income (ttm) -312.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -183.80%
Debt to Equity Ratio 0.00
Volume 1,490,700
Avg Vol 1,120,704
Day's Range N/A - N/A
Shares Out 60.59M
Stochastic %K 54%
Beta 1.58
Analysts Hold
Price Target $8.67

Company Profile

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the re...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 422 5362
Address:
27 Drydock Avenue, 8th Floor, Boston, United States
madnessofcrowds
madnessofcrowds Mar. 20 at 8:08 PM
$DNA holding up just fine at these ridiculous levels
1 · Reply
look2hook
look2hook Mar. 20 at 3:00 PM
$DNA Always a good short trade here over 6.90.
0 · Reply
Mingjun_sadbear
Mingjun_sadbear Mar. 20 at 2:10 PM
$DNA whos still here?
1 · Reply
Shaffin786
Shaffin786 Mar. 20 at 7:35 AM
$DNA DNA is not a stock, it’s a bet on the future of biology as infrastructure.
0 · Reply
Shaffin786
Shaffin786 Mar. 20 at 7:22 AM
$DNA 🚀 Strategic importance for $DNA This is bigger than “food coloring”: 👉 It’s a proof-of-business model • Precision fermentation → real revenue streams • Replaces synthetic dyes → large global market • ESG + health tailwinds (very strong demand) 👉 It opens the door to: • More ingredients (colors, flavors, proteins) • Partnerships with major food companies • Recurring industrial biotech revenue
0 · Reply
TheHowlingMadness
TheHowlingMadness Mar. 19 at 8:38 PM
$DNA just a matter of time before that shelf gets tapped again, and ill be here for it.🤌
1 · Reply
BioAwareness
BioAwareness Mar. 19 at 7:27 PM
$DNA Phytolon's beetroot-red food coloring was granted FDA approval. Regardless of DNA's stock performance, It's a great milestone.
1 · Reply
SuperGreenToday
SuperGreenToday Mar. 19 at 12:49 PM
$DNA Share Price: $6.49 Contract Selected: Sep 18, 2026 $5 Calls Buy Zone: $2.29 – $2.84 Target Zone: $3.99 – $4.88 Potential Upside: 64% ROI Time to Expiration: 182 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
honestinvt7672
honestinvt7672 Mar. 19 at 6:45 AM
$DNA Jason Kelly
0 · Reply
CallMeMyBeer
CallMeMyBeer Mar. 18 at 8:33 PM
$DNA Bulls be like " Brace yourself, hang on tight! I AIN'T LEAVING!" Ain't that right @papertrader_US @Polish_Assassin @PolishAssassin__ ? 😂😂😂😂😂
0 · Reply
Latest News on DNA
Ginkgo Bioworks Launches Ginkgo Cloud Lab, Powered by Autonomous Lab Infrastructure

Mar 2, 2026, 8:00 AM EST - 19 days ago

Ginkgo Bioworks Launches Ginkgo Cloud Lab, Powered by Autonomous Lab Infrastructure

Ginkgo Bioworks Pivots To AI And Robotics After Rough Quarter

Feb 27, 2026, 11:50 AM EST - 22 days ago

Ginkgo Bioworks Pivots To AI And Robotics After Rough Quarter

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business

Feb 26, 2026, 4:26 PM EST - 23 days ago

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business

Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2025 Results Presentation

Feb 19, 2026, 8:00 AM EST - 4 weeks ago

Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2025 Results Presentation

Ginkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural Products

Feb 18, 2026, 8:00 AM EST - 4 weeks ago

Ginkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural Products

Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark

Feb 5, 2026, 2:00 PM EST - 6 weeks ago

Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark

Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 8:00 AM EST - 2 months ago

Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach

Dec 22, 2025, 1:21 PM EST - 3 months ago

Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach

Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment

Dec 17, 2025, 8:00 AM EST - 3 months ago

Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment

ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies

Dec 11, 2025, 8:46 AM EST - 3 months ago

ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies

Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety

Dec 9, 2025, 8:00 AM EST - 3 months ago

Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety

Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC

Dec 5, 2025, 8:33 AM EST - 3 months ago

Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC

STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy

Dec 3, 2025, 8:00 AM EST - 3 months ago

STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy

Ginkgo Bioworks Partners on Illinois-Led Team to Develop Innovative New Treatments for Oral Health

Nov 18, 2025, 8:00 AM EST - 4 months ago

Ginkgo Bioworks Partners on Illinois-Led Team to Develop Innovative New Treatments for Oral Health

Ginkgo Bioworks Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 4 months ago

Ginkgo Bioworks Reports Third Quarter 2025 Financial Results

Ginkgo Bioworks Awarded Project Agreement through BARDA's BioMaP-Consortium

Nov 3, 2025, 8:00 AM EST - 4 months ago

Ginkgo Bioworks Awarded Project Agreement through BARDA's BioMaP-Consortium

DCI

Ginkgo Bioworks and Bayer Extend Multi-Year Strategic Partnership to Accelerate Next Generation Biological Solutions for Agriculture

Oct 31, 2025, 8:00 AM EDT - 5 months ago

Ginkgo Bioworks and Bayer Extend Multi-Year Strategic Partnership to Accelerate Next Generation Biological Solutions for Agriculture

Ginkgo Bioworks Announces Date of Third Quarter 2025 Results Presentation

Oct 30, 2025, 4:05 PM EDT - 5 months ago

Ginkgo Bioworks Announces Date of Third Quarter 2025 Results Presentation

Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program

Oct 23, 2025, 8:00 AM EDT - 5 months ago

Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program

Ginkgo Datapoints and Apheris Launch Antibody Developability Consortium

Sep 4, 2025, 8:00 AM EDT - 7 months ago

Ginkgo Datapoints and Apheris Launch Antibody Developability Consortium

Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions

Aug 29, 2025, 4:05 PM EDT - 7 months ago

Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry

Aug 20, 2025, 8:01 AM EDT - 7 months ago

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry

Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth

Aug 12, 2025, 8:01 AM EDT - 7 months ago

Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth

Ginkgo Bioworks Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 5:01 PM EDT - 8 months ago

Ginkgo Bioworks Reports Second Quarter 2025 Financial Results

Ginkgo Bioworks Announces Date of Second Quarter 2025 Results Presentation

Jul 31, 2025, 8:01 AM EDT - 8 months ago

Ginkgo Bioworks Announces Date of Second Quarter 2025 Results Presentation

Ginkgo to Deploy Modular Automation Technology to the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Labs (PNNL) to Accelerate Microbial Research for the Bioeconomy

Jul 30, 2025, 9:01 AM EDT - 8 months ago

Ginkgo to Deploy Modular Automation Technology to the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Labs (PNNL) to Accelerate Microbial Research for the Bioeconomy

Ginkgo Bioworks Launches ADME Profiling Service Using Lab Automation, Offering a US-based Operation That Will Match or Beat Pricing Quotes from Chinese or Other International Vendors

Jul 17, 2025, 9:01 AM EDT - 8 months ago

Ginkgo Bioworks Launches ADME Profiling Service Using Lab Automation, Offering a US-based Operation That Will Match or Beat Pricing Quotes from Chinese or Other International Vendors

Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer

May 21, 2025, 4:05 PM EDT - 10 months ago

Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer

Twist Bioscience and Ginkgo Bioworks Revise Collaboration

May 8, 2025, 8:00 AM EDT - 11 months ago

Twist Bioscience and Ginkgo Bioworks Revise Collaboration

TWST

Ginkgo Bioworks Reports First Quarter 2025 Financial Results

May 6, 2025, 5:00 PM EDT - 11 months ago

Ginkgo Bioworks Reports First Quarter 2025 Financial Results

Phytolon and Ginkgo Bioworks Boost Natural Food Colors by Hitting Full-Project Milestone, Nearly Tripling the Manufacturing Efficiency of Phytolon's Innovative Colors

Apr 30, 2025, 9:00 AM EDT - 11 months ago

Phytolon and Ginkgo Bioworks Boost Natural Food Colors by Hitting Full-Project Milestone, Nearly Tripling the Manufacturing Efficiency of Phytolon's Innovative Colors

Ginkgo Bioworks Announces Date of First Quarter 2025 Results Presentation

Apr 29, 2025, 4:00 PM EDT - 11 months ago

Ginkgo Bioworks Announces Date of First Quarter 2025 Results Presentation

Ginko Automation Partners with Aura Genetics to Accelerate Direct-to-Consumer Testing and Innovation

Apr 22, 2025, 9:00 AM EDT - 11 months ago

Ginko Automation Partners with Aura Genetics to Accelerate Direct-to-Consumer Testing and Innovation

Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain

Apr 10, 2025, 9:00 AM EDT - 1 year ago

Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain

DCI

Plex Research Partners With Ginkgo Bioworks on Artificial Intelligence (AI)-Powered Drug Discovery to Identify Novel Disease Mechanisms and Pathways

Apr 3, 2025, 9:01 AM EDT - 1 year ago

Plex Research Partners With Ginkgo Bioworks on Artificial Intelligence (AI)-Powered Drug Discovery to Identify Novel Disease Mechanisms and Pathways

Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Feb 26, 2025, 8:10 AM EST - 1 year ago

Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

FLYW

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 25, 2025, 5:00 PM EST - 1 year ago

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results

Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab

Feb 21, 2025, 9:00 AM EST - 1 year ago

Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab

Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care

Feb 20, 2025, 8:01 AM EST - 1 year ago

Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care

Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2024 Results Presentation

Feb 18, 2025, 8:00 AM EST - 1 year ago

Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2024 Results Presentation

Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series

Feb 6, 2025, 8:01 AM EST - 1 year ago

Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series

Ginkgo Automation to Deploy Flexible Laboratory Automation System for Cutting-Edge Biofuels and Bioproducts Research at Great Lakes Bioenergy Research Center (GLBRC)

Jan 23, 2025, 8:01 AM EST - 1 year ago

Ginkgo Automation to Deploy Flexible Laboratory Automation System for Cutting-Edge Biofuels and Bioproducts Research at Great Lakes Bioenergy Research Center (GLBRC)

SaponiQx, Probius, and Ginkgo Bioworks Unite to Revolutionize Vaccine Adjuvant Development

Jan 21, 2025, 7:00 AM EST - 1 year ago

SaponiQx, Probius, and Ginkgo Bioworks Unite to Revolutionize Vaccine Adjuvant Development

Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors

Jan 13, 2025, 8:01 AM EST - 1 year ago

Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors

Rapid Rise of Synthetic Biology Fuels Enzymatic DNA Synthesis Boom Across Biopharma and Genomics

Jan 9, 2025, 11:38 AM EST - 1 year ago

Rapid Rise of Synthetic Biology Fuels Enzymatic DNA Synthesis Boom Across Biopharma and Genomics

Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:00 AM EST - 1 year ago

Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program

Dec 17, 2024, 8:11 AM EST - 1 year ago

Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program

Ginkgo Bioworks Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 5:01 PM EST - 1 year ago

Ginkgo Bioworks Reports Third Quarter 2024 Financial Results

Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing

Nov 12, 2024, 8:01 AM EST - 1 year ago

Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing

Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Presentation

Nov 5, 2024, 7:00 AM EST - 1 year ago

Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Presentation

madnessofcrowds
madnessofcrowds Mar. 20 at 8:08 PM
$DNA holding up just fine at these ridiculous levels
1 · Reply
look2hook
look2hook Mar. 20 at 3:00 PM
$DNA Always a good short trade here over 6.90.
0 · Reply
Mingjun_sadbear
Mingjun_sadbear Mar. 20 at 2:10 PM
$DNA whos still here?
1 · Reply
Shaffin786
Shaffin786 Mar. 20 at 7:35 AM
$DNA DNA is not a stock, it’s a bet on the future of biology as infrastructure.
0 · Reply
Shaffin786
Shaffin786 Mar. 20 at 7:22 AM
$DNA 🚀 Strategic importance for $DNA This is bigger than “food coloring”: 👉 It’s a proof-of-business model • Precision fermentation → real revenue streams • Replaces synthetic dyes → large global market • ESG + health tailwinds (very strong demand) 👉 It opens the door to: • More ingredients (colors, flavors, proteins) • Partnerships with major food companies • Recurring industrial biotech revenue
0 · Reply
TheHowlingMadness
TheHowlingMadness Mar. 19 at 8:38 PM
$DNA just a matter of time before that shelf gets tapped again, and ill be here for it.🤌
1 · Reply
BioAwareness
BioAwareness Mar. 19 at 7:27 PM
$DNA Phytolon's beetroot-red food coloring was granted FDA approval. Regardless of DNA's stock performance, It's a great milestone.
1 · Reply
SuperGreenToday
SuperGreenToday Mar. 19 at 12:49 PM
$DNA Share Price: $6.49 Contract Selected: Sep 18, 2026 $5 Calls Buy Zone: $2.29 – $2.84 Target Zone: $3.99 – $4.88 Potential Upside: 64% ROI Time to Expiration: 182 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
honestinvt7672
honestinvt7672 Mar. 19 at 6:45 AM
$DNA Jason Kelly
0 · Reply
CallMeMyBeer
CallMeMyBeer Mar. 18 at 8:33 PM
$DNA Bulls be like " Brace yourself, hang on tight! I AIN'T LEAVING!" Ain't that right @papertrader_US @Polish_Assassin @PolishAssassin__ ? 😂😂😂😂😂
0 · Reply
RicardoNA
RicardoNA Mar. 18 at 8:55 AM
$DNA jump above 7 and run!
1 · Reply
Shaffin786
Shaffin786 Mar. 18 at 3:56 AM
$DNA https://finance.yahoo.com/news/ginkgo-bioworks-dna-story-shifting-160808020.html
0 · Reply
secretcasino
secretcasino Mar. 17 at 4:40 PM
$SDOT If any of my speculation is correct they might be waiting to hold off on the 10-K until 3/23 to be a strategic move to align the financial audit with the March 23rd FDA approval effective date for Phytolon’s Beetroot Red. This timing allows Oren Attiya—who serves as both Sadot’s interim CFO and CEO of Millennium Food-Tech—to potentially consolidate the merger and commercial launch into a single transformative announcement. Wondering if the folks at $DNA are aware that this natural food coloring that is made for Phytolon in Ginko's labs will be ready to hit the US market after 3/23?
2 · Reply
CallMeMyBeer
CallMeMyBeer Mar. 17 at 12:31 AM
$DNA Lol crazy how the most bullish person you have here is weak hands @jaydilks 😂😂😂😂😂
1 · Reply
secretcasino
secretcasino Mar. 13 at 7:04 PM
$DNA Correct me if I'm wrong.. I haven't seen anyone mention Phytolon's (a Millennium Food Tech Company) very recent FDA approval here. Ginkgo Bioworks has been producing the "Beetroot Red" natural food dyes for Phytolon since 2022. The current CEO of Millennium Food Tech has taken a contract/hourly CFO role for $SDOT Sadot Group has also recently received an injection of Israeli VC money in exchange for Series A shares for Sadot. Some speculation on my end is pointing towards a Nasdaq shell takeover for Phytolon to be listed on an American exchange. Anyone else have thoughts on this?
0 · Reply
RicardoNA
RicardoNA Mar. 13 at 3:30 PM
$DNA lets see if it can hold any gains
0 · Reply
TheHowlingMadness
TheHowlingMadness Mar. 13 at 2:36 PM
$DNA loaded a few more puts here. Have a good weekend folks. 👊
0 · Reply
look2hook
look2hook Mar. 13 at 2:32 PM
$DNA This dog is a traders dream. Sell short and 6.90 and cover around 6.40. It's the gift that keeps on printing.
1 · Reply
Shaffin786
Shaffin786 Mar. 13 at 6:54 AM
$DNA Why some long-term investors stay Bull case investors believe: If automated biology works, the TAM is enormous. The global bio-economy could reach $4–30 trillion by 2040. If Ginkgo becomes a core platform, the upside is asymmetric.
0 · Reply
Shaffin786
Shaffin786 Mar. 13 at 3:43 AM
$DNA Ginkgo is not competing with Chinese fermentation companies. They operate in different layers: • Ginkgo → design organisms • China → mass produce molecules If Ginkgo succeeds, they could become the Intel or Nvidia of biology, while fermentation companies become the TSMC factories.
0 · Reply
Shaffin786
Shaffin786 Mar. 13 at 3:32 AM
$DNA https://open.substack.com/pub/sepiabio/p/bio-asia-chinese-biofermentation?r=299boh&utm_campaign=post&utm_medium=web
0 · Reply
v92
v92 Mar. 13 at 12:56 AM
$DNA Literally. What the F is this?! What the hell does this company do???? “Ginkgo Bioworks (NYSE: DNA) today announced the official launch of Ginkgo Cloud Lab. This new interface allows researchers to transition their benchwork to Ginkgo's autonomous lab infrastructure directly through a web browser.”
2 · Reply